How is secondary hyperparathyroidism managed?

Updated: Dec 24, 2020
  • Author: Lawrence T Kim, MD, FACS, FACE; Chief Editor: Romesh Khardori, MD, PhD, FACP  more...
  • Print


Unlike primary hyperparathyroidism, medical management is the mainstay of treatment for secondary hyperparathyroidism.

Correcting vitamin D deficiency may be achieved using cholecalciferol (vitamin D3) or ergocalciferol (vitamin D2). Recommended therapy for patients with vitamin D deficiency is 50,000 IU of vitamin D2 or D3 once a week for 8 weeks and then supplementation with 800 IU daily indefinitely. 

For patients with CKD, the National Kidney Foundation (NKF) published clinical practice guidelines as part of its Kidney Disease Outcomes Quality Initiative (KDOQI). In general, it has been recommended to reduce parathyroid hormone levels to within a range that supports normal bone turnover and minimizes ectopic calcification.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!